 |
|
Newer Drug Therapy for Congestive Heart Failure
Eugene Coodley, MD, MACP
Arch Intern Med. 1999;159:1177-1183.
Background The management of congestive heart failure has undergone a number of modifications over the past 5 to 10 years.
Methods These include assaying the role of inotropic drugs, evaluating the role of phosphodiesterase inhibitors, considering the role of intermittent inotropic infusion in ambulatory patients, and recognizing the importance of angiotensin-converting enzyme inhibitors. Very recently, the important role of angiotensin II receptor blocking agents and the use of beta blockade have provided additional modalities for the control of congestive heart failure. The relative usefulness of such therapy has been reviewed in this article.
Conclusion The management of congestive heart failure has undergone considerable change with the use of newer and more effective drugs.
From the University of California, Irvine, and the Chief Internal Medicine Section, Department of Veterans Affairs Medical Center, Long Beach, Calif.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(11):1259-1260.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Pilot Safety Trial of Prolonged (48 h) Infusion of the Dual Endothelin-Receptor Antagonist Tezosentan in Patients With Advanced Heart Failure
Torre-Amione et al.
Chest 2001;120:460-466.
ABSTRACT
| FULL TEXT
Hemodynamic Effects of Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist, in Patients With Class III to IV Congestive Heart Failure
Torre-Amione et al.
Circulation 2001;103:973-980.
ABSTRACT
| FULL TEXT
|
